These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 24295065)

  • 1. PEGylated nanomedicines: recent progress and remaining concerns.
    Vllasaliu D; Fowler R; Stolnik S
    Expert Opin Drug Deliv; 2014 Jan; 11(1):139-54. PubMed ID: 24295065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEGylated polyester-based nanoncologicals.
    Conte C; d'Angelo I; Miro A; Ungaro F; Quaglia F
    Curr Top Med Chem; 2014; 14(9):1097-114. PubMed ID: 24678711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs.
    Parveen S; Sahoo SK
    Clin Pharmacokinet; 2006; 45(10):965-88. PubMed ID: 16984211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silica-Based Nanoparticles for Biomedical Applications: From Nanocarriers to Biomodulators.
    Yang Y; Zhang M; Song H; Yu C
    Acc Chem Res; 2020 Aug; 53(8):1545-1556. PubMed ID: 32667182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns.
    Zhang X; Wang H; Ma Z; Wu B
    Expert Opin Drug Metab Toxicol; 2014 Dec; 10(12):1691-702. PubMed ID: 25270687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
    van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polypeptides as alternatives to PEGylation of therapeutic agents.
    Chen H; Zhang Q
    Expert Opin Drug Deliv; 2024; 21(1):1-12. PubMed ID: 38116624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevant Physicochemical Descriptors of "Soft Nanomedicines" to Bypass Biological Barriers.
    Nino-Pariente A; Nebot VJ; Vicent MJ
    Curr Pharm Des; 2016; 22(9):1274-91. PubMed ID: 26675217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution.
    Hussain Z; Khan S; Imran M; Sohail M; Shah SWA; de Matas M
    Drug Deliv Transl Res; 2019 Jun; 9(3):721-734. PubMed ID: 30895453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanovesicular carriers as alternative drug delivery systems: ethosomes in focus.
    Mbah CC; Builders PF; Attama AA
    Expert Opin Drug Deliv; 2014 Jan; 11(1):45-59. PubMed ID: 24294974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymer-drug conjugates: origins, progress to date and future directions.
    Kopeček J
    Adv Drug Deliv Rev; 2013 Jan; 65(1):49-59. PubMed ID: 23123294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Membrane-encapsulated camouflaged nanomedicines in drug delivery.
    Ghosh S; Girigoswami K; Girigoswami A
    Nanomedicine (Lond); 2019 Aug; 14(15):2067-2082. PubMed ID: 31355709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand-targeted theranostic nanomedicines against cancer.
    Yao VJ; D'Angelo S; Butler KS; Theron C; Smith TL; Marchiò S; Gelovani JG; Sidman RL; Dobroff AS; Brinker CJ; Bradbury ARM; Arap W; Pasqualini R
    J Control Release; 2016 Oct; 240():267-286. PubMed ID: 26772878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A journey through the history of PEGylated drug delivery nanocarriers.
    López-Estevez AM; Gref R; Alonso MJ
    Drug Deliv Transl Res; 2024 Aug; 14(8):2026-2031. PubMed ID: 38796665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanotechnology Inspired Advanced Engineering Fundamentals for Optimizing Drug Delivery.
    Kassem AA
    Curr Drug Targets; 2018; 19(15):1839-1854. PubMed ID: 29412103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomedicines: The magic bullets reaching their target?
    Flühmann B; Ntai I; Borchard G; Simoens S; Mühlebach S
    Eur J Pharm Sci; 2019 Feb; 128():73-80. PubMed ID: 30465818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PEG - a versatile conjugating ligand for drugs and drug delivery systems.
    Kolate A; Baradia D; Patil S; Vhora I; Kore G; Misra A
    J Control Release; 2014 Oct; 192():67-81. PubMed ID: 24997275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nano based drug delivery systems: recent developments and future prospects.
    Patra JK; Das G; Fraceto LF; Campos EVR; Rodriguez-Torres MDP; Acosta-Torres LS; Diaz-Torres LA; Grillo R; Swamy MK; Sharma S; Habtemariam S; Shin HS
    J Nanobiotechnology; 2018 Sep; 16(1):71. PubMed ID: 30231877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are existing standard methods suitable for the evaluation of nanomedicines: some case studies.
    Gioria S; Caputo F; Urbán P; Maguire CM; Bremer-Hoffmann S; Prina-Mello A; Calzolai L; Mehn D
    Nanomedicine (Lond); 2018 Mar; 13(5):539-554. PubMed ID: 29381129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PEGylated polymers for medicine: from conjugation to self-assembled systems.
    Joralemon MJ; McRae S; Emrick T
    Chem Commun (Camb); 2010 Mar; 46(9):1377-93. PubMed ID: 20162127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.